Production of orphan medicines at BioConnection is growing fast

For Mibiton, the two million euro investment in BioConnection formed a uniquely shared GMP-production facility, where young (bio)pharmaceutical companies could manufacture products for their first clinical trials. What happened since its twelve-year existence reads like an exciting book whereby the last chapter has yet to be written. You can read the recent interview with CEO Alexander Willemse here.

  

Afdrukken